Review anchor
T cell surface glycoprotein CD3
PROTEIN COMPLEX · Homo sapiens
As of 2026-09-13
Evidence Snapshot
T cell surface glycoprotein CD3
CHEMBL2364168
PROTEIN COMPLEX
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats T cell surface glycoprotein CD3 as ChEMBL target CHEMBL2364168, mapped to UniProt P07766. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL2364168
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P07766
T-cell surface glycoprotein CD3 epsilon chain
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why T cell surface glycoprotein CD3 matters
T cell surface glycoprotein CD3 is reviewed as T-cell surface glycoprotein CD3 epsilon chain (UniProt P07766); T cell surface glycoprotein CD3 shows approved-linked disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block.; 11 linked drugs keep this evidence frame grounded..
Protein context
T-cell surface glycoprotein CD3 epsilon chain
T-cell surface glycoprotein CD3 epsilon chain Sequence length is 207 aa.
Review this target as T cell surface glycoprotein CD3, mapped to UniProt P07766. ChEMBL maps the protein component as T-cell surface glycoprotein CD3 epsilon chain. Sequence length is 207 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt P07766
Protein
Disease context
neoplasm
T cell surface glycoprotein CD3 shows approved-linked disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block. 11 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include BLINATUMOMAB, CATUMAXOMAB, ELRANATAMAB.
Start review with neoplasm because it currently carries approved-linked support. Linked drugs include BLINATUMOMAB, CATUMAXOMAB, ELRANATAMAB, EPCORITAMAB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Approved-linked
11 linked drugs
Activity base
Portfolio and assay base
ChEMBL currently tracks 0 approved drugs, 0 compounds, and 0 assays for this target.
Activity source · ChEMBL 36 via Core EngineSource Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why T cell surface glycoprotein CD3 matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt P07766, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why neoplasm is currently treated as approved-linked support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
0
Total Compounds
0
Total Assays
0
Approved Drugs
-
Activity Types
pChEMBL Activity Distribution
Source Header